ATNM - Actinium Pharmaceuticals - Stock Forecast

Healthcare - Sector

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ATNM is currently covered by 1 analysts with an average price target of $4.09. This is a potential upside of $2.3 (128.49%) from yesterday's end of day stock price of $1.79.

Actinium Pharmaceuticals's activity chart (see below) currently has 4 price targets and 28 ratings on display. The stock rating distribution of ATNM is 100% BUY.

Stock Analyst Price Targets - Review

Highest price target for ATNM is $4, Lowest price target is $4, average price target is $4.

Most recent stock forecast was given by JOSEPH PANTGINIS from HCWAINWRIGHT on 24-Jun-2025. First documented stock forecast 04-Jun-2020.

Best performing analysts who are covering ATNM - Actinium Pharmaceuticals:

Joseph Pantginis

Currently out of the existing stock ratings of ATNM, 21 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Joseph Pantginis (HCWAINWRIGHT)

Buy

$2.21 (123.46%)

1 months 2 days ago
(24-Jun-2025)

0/25 (0%)

$2.3 (135.29%)

Please subscribe to see the analyst performance score

Show more analysts

Load Price Targets and Ratings Chart

To gain access for the analyst/ stock price target chart please use a computer

What is ATNM (Actinium Pharmaceuticals) average time for price targets to be met?

On average it took 0 days on average for the stock forecasts to be realized with a an average price target met ratio 0

Which analyst has the current highest performing score on ATNM (Actinium Pharmaceuticals) with a proven track record?

JOSEPH PANTGINIS

Which analyst has the most public recommendations on ATNM (Actinium Pharmaceuticals)?

Joseph Pantginis works at HC WAINWRIGHT and has 32 price targets and 24 ratings on ATNM

Which analyst is the currently most bullish on ATNM (Actinium Pharmaceuticals)?

Joseph Pantginis with highest potential upside - $2.21

Actinium Pharmaceuticals in the News

ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or “the Company”) (NYSE: ATNM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against...

ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022...